Some businesses are built to last — and in the share market, those are the ones worth holding for decades.
They combine strong competitive advantages, large and growing markets, and the ability to compound earnings year after year.
Here are three unstoppable Australian shares that analysts think could reward patient investors over the next two decades:
CSL Ltd (ASX: CSL)
CSL is one of the world's leading biotechnology companies, specialising in plasma therapies, vaccines, and specialty medicines. It operates in a highly regulated industry with substantial barriers to entry, giving it a strong competitive moat.
The Australian share has delivered decades of revenue and earnings growth, driven by innovation, global expansion, and a deep research pipeline. With rising global healthcare demand and new therapies in development, CSL has a long runway ahead.
It is not the cheapest share on the market, but quality rarely is — and for long-term investors, CSL's track record speaks for itself.
Bell Potter currently rates CSL as a buy with a $305.00 price target.
NextDC Ltd (ASX: NXT)
Another unstoppable Australian share is NextDC. It operates a network of premium data centres across Australia, serving as critical infrastructure for cloud computing, AI, and the broader digital economy. Demand for data storage and processing capacity continues to surge as more businesses move online and adopt emerging technologies.
With long-term contracts, high switching costs, and strategic land holdings in key cities, NextDC is well-positioned to capture this growth. The company is also expanding internationally, further extending its potential market.
Given the rise of AI and ever-growing data consumption, NextDC's services are only going to become more essential in the decades ahead.
Morgans is a fan of the company and has a buy rating and $18.80 price target on its shares.
WiseTech Global Ltd (ASX: WTC)
WiseTech develops and sells the CargoWise software platform, which is used by thousands of logistics companies worldwide to manage supply chains. This mission-critical software is deeply embedded in its customers' operations, leading to sticky recurring revenue and high switching costs.
The Australian share has been expanding its capabilities through both organic growth and strategic acquisitions, steadily increasing its global market share. As international trade becomes more complex, demand for WiseTech's solutions should continue to grow.
For investors looking for scalable, founder-led growth, WiseTech is one of the ASX's premier technology stories.
UBS is bullish and has a buy rating and $145.00 price target on its shares.
